The combined use of BRAF and MEK inhibitors against melanoma has been found to upregulate MHC levels and melanoma differentiation antigens, such as gp-100 and melanoma-associated antigen recognized by T cells (MART-1) [28]. This evidence concerns the gene PMEL and melanoma.